BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 10802357)

  • 1. 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review.
    Fiveash JB; Hanks G; Roach M; Wang S; Vigneault E; McLaughlin PW; Sandler HM
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):335-42. PubMed ID: 10802357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External beam radiotherapy dose response of prostate cancer.
    Pollack A; Zagars GK
    Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1011-8. PubMed ID: 9392538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era.
    Pollack A; Smith LG; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):507-12. PubMed ID: 10974469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose response in prostate cancer with 8-12 years' follow-up.
    Hanks GE; Hanlon AL; Epstein B; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):427-35. PubMed ID: 12243818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.
    Kuban DA; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Zietman AL
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):915-28. PubMed ID: 14575822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treated with three-dimensional conformal external beam radiation therapy.
    Anderson PR; Hanlon AL; Horwitz E; Pinover W; Hanks GE
    Cancer; 2000 Dec; 89(12):2565-9. PubMed ID: 11135217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer.
    Fukunaga-Johnson N; Sandler HM; McLaughlin PW; Strawderman MS; Grijalva KH; Kish KE; Lichter AS
    Int J Radiat Oncol Biol Phys; 1997 May; 38(2):311-7. PubMed ID: 9226317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
    Zagars GK; Pollack A; Smith LG
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hazards of dose escalation in prostate cancer radiotherapy.
    Kuban D; Pollack A; Huang E; Levy L; Dong L; Starkschall G; Rosen I
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1260-8. PubMed ID: 14630260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate.
    Roach M; Meehan S; Kroll S; Weil M; Ryu J; Small EJ; Margolis LW; Presti J; Carroll PC; Phillips TL
    J Urol; 1996 Nov; 156(5):1719-23. PubMed ID: 8863578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis.
    Livsey JE; Cowan RA; Wylie JP; Swindell R; Read G; Khoo VS; Logue JP
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1254-9. PubMed ID: 14630259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-dimensional conformal therapy versus standard radiation therapy in localized carcinoma of prostate: an update.
    Perez CA; Michalski JM; Mansur D; Lockett MA
    Clin Prostate Cancer; 2002 Sep; 1(2):97-104. PubMed ID: 15046700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapy.
    Symon Z; Griffith KA; McLaughlin PW; Sullivan M; Sandler HM
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):384-90. PubMed ID: 12957249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 1989 patterns of care study for prostate cancer: five-year outcomes.
    Chuba PJ; Moughan J; Forman JD; Owen J; Hanks G
    Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):325-34. PubMed ID: 11380218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.
    Beard CJ; Chen MH; Cote K; Loffredo M; Renshaw AA; Hurwitz M; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):19-24. PubMed ID: 14697416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate.
    Lyons JA; Kupelian PA; Mohan DS; Reddy CA; Klein EA
    Urology; 2000 Jan; 55(1):85-90. PubMed ID: 10654900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.